Start here if you're new
what it is
Eledon is a 31-person biotech trying to use one antibody, tegoprubart, to stop organ rejection and maybe help ALS.
how it gets paid
Last year Eledon Pharma made n/a in revenue. Kidney transplant prevention was the main engine at $0M, or 40% of sales.
what just happened
Latest-quarter EPS was -$0.42, and revenue was not reported.
At a glance
B balance sheet — gets the job done, barely
35/100 earnings predictability — expect surprises
-$0.75 fy2024 eps est
1.2 beta
~$213M market cap
xvary composite: 40/100 — below average
What they do
Eledon is a 31-person biotech trying to use one antibody, tegoprubart, to stop organ rejection and maybe help ALS.
31 employees versus a $213M market cap is the whole joke. The market is paying for the drug, not the office furniture. Tegoprubart is the only named lead asset, so one result can move the whole story.
How they make money
n/a
annual revenue
Kidney transplant prevention
$0M
Other transplant uses
$0M
ALS program
$0M
Platform research
$0M
The products that matter
transplant rejection therapy
tegoprubart
Phase 2 · only clinical asset
it is the entire pipeline story. 100% of the company's clinical value rides on a Phase 2 program with data from 127 patients.
one-asset company
Key numbers
$0.75
FY2024 EPS est
That is the annual loss estimate. It means the business is still paying for trials, not profits.
$213M
market cap
That is the whole equity value. One trial result can move a big piece of it.
$0M
TTM revenue
No sales means no cushion. Your stake lives on clinical data, not customers.
31
employees
A 31-person team is lean. It also means one miss can hit the whole plan.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ELDN right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest-quarter EPS was -$0.42, and revenue was not reported.
EDGAR shows no quarterly revenue figure. The clean read is simple: the company is still losing money, and the FY2024 EPS estimate is -$0.75.
$0M
revenue
-$0.42
eps
n/a
n/a
EPS loss
The -$0.42 loss matters because $0M revenue leaves no sales cushion.
source: EDGAR, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is tegoprubart failing to hold up in larger kidney transplant studies.
med
single-asset failure
tegoprubart is the only clinical asset on the page. if the efficacy or safety profile breaks, the core equity story breaks with it.
impact: 100% of the pipeline narrative sits in one program.
med
no revenue cushion
there is no approved product and no operating revenue. that means there is no commercial engine to offset trial delays or disappointing data.
impact: revenue remains at zero unless the drug reaches market.
med
finite cash runway
the company reported $57.5M in cash and runway into Q2 2027. that is useful time, but drug development calendars have a habit of slipping.
impact: if the timeline stretches, new capital likely arrives before approval economics do.
med
standard-of-care inertia
tacrolimus is entrenched in transplant medicine. better data is necessary, but physicians and regulators still need enough evidence to justify changing practice.
impact: promising Phase 2 data from 127 patients still has to scale into broader adoption evidence.
you own a company with zero product revenue, one Phase 2 asset, and $57.5M in cash to bridge the gap to Q2 2027. that is a real setup for upside and a very real setup for dilution or failure.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
cash runway into Q2 2027
this is the calendar on the wall. every quarter without a major setback makes it more useful. every delay makes it feel shorter.
trend
durability of the 24-month transplant data
longer follow-up is the whole game in transplant medicine. you want the kidney-function advantage and side-effect profile to keep holding.
metric
quarterly loss versus the -$0.75 full-year EPS frame
for a pre-revenue biotech, income statement discipline is really runway discipline. if burn rises, financing risk arrives earlier.
risk
whether the regulatory path gets clearer or murkier
orphan drug designation offers 7 years of exclusivity if approved. it does not shorten the burden of proof before approval.
Analyst rankings
earnings predictability
35 / 100
in human-speak, analysts do not expect smooth, repeatable quarters here. pre-revenue biotech rarely gives you that.
risk rank
4
this sits on the riskier end of the market. safer than 20% of stocks means riskier than most.
source: institutional data
Institutional activity
institutional ownership data for ELDN is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive